Howard Koch, MD
Internal Medicine · Sunrise, FLNPI 1003872375
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations.
Across 123 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$528
- Otsuka America Pharmaceutical, Inc.$362
- Gilead$261
- Pfizer$252
- Johnson & Johnson$206
- Novartis$132
- plus $686 from 15 others
Across 342 payments — averaging $16,400 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$2.2M
- Modernatx, Inc.$1.8M
- Eli Lilly$868K
- Tolmar, Inc.$356K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$300K
- AstraZeneca$30K
- plus $55K from 2 others
What the payments were for
- Food & beverage$2,427100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 33 | $528 |
| Otsuka America Pharmaceutical, Inc. | 14 | $362 |
| Gilead | 13 | $261 |
| Pfizer | 13 | $252 |
| Johnson & Johnson | 11 | $206 |
| Novartis | 7 | $132 |
| Astellas Pharma US Inc | 6 | $127 |
| Sumitomo Pharma America, Inc. | 4 | $100 |
| Neurocrine Biosciences, Inc. | 2 | $74 |
| Eisai Inc. | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $57 |
| Boehringer Ingelheim | 2 | $46 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $37 |
| Bayer | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$2,427 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 356 | $206,031 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 29 | $126,170 |
| IngrezzaValbenazine Tosylate | 36 | $82,341 |
| XareltoRivaroxaban | 127 | $58,194 |
| TrulicityDulaglutide | 44 | $52,266 |
| OzempicSemaglutide | 45 | $47,382 |
| JardianceEmpagliflozin | 51 | $47,135 |
| JanuviaSitagliptin Phosphate | 42 | $28,212 |
| LinzessLinaclotide | 38 | $21,601 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $18,431 |
| TradjentaLinagliptin | 12 | $15,692 |
| MyrbetriqMirabegron | 47 | $15,676 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $15,185 |
| Bydureon BciseExenatide Microspheres | 23 | $11,306 |
| Atorvastatin Calcium | 831 | $11,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $252 | $206,031356 claims |
| GileadBiktarvy | $261 | $126,17029 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $74 | $82,34136 claims |
| Johnson & JohnsonXarelto, Procrit | $206 | $65,354140 claims |
| Boehringer IngelheimJardiance, Tradjenta | $46 | $62,82763 claims |
| Lilly USA, LLCTrulicity | $17 | $52,26644 claims |
| Astellas Pharma US IncMyrbetriq | $127 | $15,67647 claims |
| NovartisEntresto | $132 | $10,31218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Sunrise
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.